Twist Bioscience Upsizes Offering to $300M, Betting Big on AI and Scale

SOUTH SAN FRANCISCO, CA – August 05, 2026 – In a strong display of investor confidence, synthetic biology leader Twist Bioscience Corporation (Nasdaq: TWST) announced the pricing of an upsized public offering, now set to raise $300 million. The move, increased from an initial $250 million target announced just a day prior, provides the company with a significant war chest to accelerate its growth in a market increasingly captivated by the intersection of artificial intelligence and drug discovery.

Twist priced 3,125,000 shares of its common stock at $96.00 per share. The gross proceeds, before deducting underwriting discounts and commissions, will fuel strategic investments in research and development, manufacturing expansion, and new product offerings. The deal, managed by a syndicate including Goldman Sachs & Co. LLC and William Blair, also grants underwriters a 30-day option to purchase up to an additional 468,750 shares, potentially adding another $45 million to the raise. This capital infusion arrives at a pivotal moment, as the company navigates the delicate balance between rapid revenue growth and the persistent pressure to achieve profitability.

A Strategic War Chest in a Rebounding Market

The timing and scale of the offering speak volumes about the current climate for biotech funding. After a period of cooling, capital has begun flowing back into the sector, with investors showing a renewed appetite for R&D-intensive companies with a clear growth narrative. The first half of 2026 saw biotech funding reach $34.3 billion, and Twist’s successful upsized offering suggests the market is receptive to companies that can demonstrate a path to innovation leadership.

However, the announcement follows a mixed signal from its recent earnings report. On August 3, Twist reported record revenue of $118.4 million for its fiscal third quarter—its 14th consecutive quarter of sequential growth. Despite this, an adjusted earnings-per-share figure that missed analyst estimates sent the stock falling in premarket trading. The offering price of $96.00 per share represents a discount from its closing price of $99.21 on August 4, a common practice to ensure a successful offering but one that reflects the market's complex calculus. For investors, the raise highlights a company capitalizing on market strength to fortify its balance sheet for the long haul.

Balancing Growth Ambitions with Financial Realities

Twist Bioscience's financial trajectory embodies the classic growth-stage biotech narrative: soaring revenues coupled with significant operating losses. While year-over-year revenue climbed an impressive 23.2%, the company's net loss for the quarter widened to $35.1 million as it ramped up spending on R&D and employee-related costs. This dynamic makes the capital raise not just opportunistic, but necessary.

As of June 30, 2026, the company held $166.8 million in cash and short-term investments. With a quarterly net loss of over $35 million, the burn rate underscored the need for fresh capital to execute its ambitious roadmap. Management has guided for achieving adjusted EBITDA breakeven by the fourth quarter of fiscal 2026 and has committed to maintaining positive EBITDA in fiscal 2027. The $300 million injection provides critical runway, allowing the company to invest in growth without the immediate pressure of near-term cash constraints, a move likely to be welcomed by long-term institutional holders focused on the company's strategic execution.

Fueling the Synthetic Biology and AI Frontier

The proceeds from the offering are earmarked for the core drivers of Twist's future. The company stands at the forefront of the synthetic biology revolution, providing the foundational tools—custom-synthesized DNA—that power innovation in therapeutics, diagnostics, agriculture, and data storage. The global synthetic biology market is projected to grow from $18.9 billion in 2025 to over $69 billion by 2033, and Twist is positioning itself to capture a significant share of that expansion.

A key area of focus is the burgeoning field of AI-enabled drug discovery. Twist's therapeutics revenue surged 49% year-over-year, largely driven by partners using artificial intelligence to design novel antibodies and other biologics. The company's platform provides the physical DNA that brings these digital designs to life. This synergy was recently highlighted by a partnership with Amazon Web Services, where Twist serves as a wet lab partner for the Amazon Bio Discovery platform, bridging the gap between AI algorithms and real-world biological experiments. Further expanding its capabilities, Twist entered a licensing agreement with Invenra to offer a sophisticated bispecific antibody platform, enhancing its value proposition for pharmaceutical clients.

Beyond R&D, the funds will support the expansion of Twist’s unique manufacturing process, which uses a proprietary silicon-based platform to synthesize DNA at a massive scale. This technology has already enabled the company to slash manufacturing costs by 60% and increase capacity fourfold over the last three years, creating a formidable competitive moat.

The Investor's Calculus: Dilution vs. Long-Term Value

For existing shareholders, the offering presents a classic trade-off. The issuance of up to 3.6 million new shares will result in a dilution of approximately 5.4% for current stockholders. This immediate impact on per-share value is the price of admission for funding the company's next phase of growth.

The bull case rests on the belief that the strategic value of the infused capital will far outweigh the dilution. By investing heavily in its high-growth segments—particularly AI-driven therapeutics and NGS tools for diagnostics—Twist aims to solidify its leadership against competitors like Ginkgo Bioworks, GenScript, and Thermo Fisher Scientific. The capital allows Twist to scale its operations, accelerate innovation, and aggressively pursue market share in the rapidly expanding oligonucleotide synthesis market, which is projected to reach nearly $33 billion by 2031.

Ultimately, the success of this offering will be judged not by the immediate stock reaction, but by Twist Bioscience's ability to convert this capital into sustained growth, market leadership, and, eventually, profitability. For now, the company has successfully refueled its tank, signaling its intent to keep its foot on the accelerator.